Visus Therapeutics Appoints Eric D. Donnenfeld, MD, to Board of Directors

Visus Therapeutics announced the appointment of Eric D. Donnenfeld, MD, to the company’s Board of Directors. Dr. Donnenfeld brings more than 30 years of clinical experience as an internationally recognized expert in refractive, cornea, and cataract surgery.

“I am thrilled to welcome Eric to the Visus Board,” Ben Bergo, co-founder and chief executive officer at Visus Therapeutics, said in a company news release. “Eric brings tremendous leadership experience, not only as a world-renowned anterior segment specialist, but also in business management and innovation. He is the founding partner in OCLI Vision, one of the leading ophthalmology and optometry practices in the United States, and he has been involved in numerous clinical stage companies. We look forward to Eric’s many contributions as Visus advances and expands on its pipeline of innovative ophthalmic products.”

“I am very much looking forward to working closely with Ben and Rhett, the Board and leadership team, as Visus pioneers many exciting new investigational drug candidates, including what may be a best-in-class topical treatment of presbyopia—Brimochol PF,” said Dr. Donnenfeld. “Beyond that, Visus’ recently announced lens modulation program offers the real possibility of a non-surgical therapy that has the potential to treat cataracts and presbyopia, improving the quality of life of millions of people around the world. I am really excited to help Visus bring these and other potentially transformative treatments to our patients.”